Analyst consensus rating
Caris Life Sciences Analyst Rating: Buy
Direct answer
Caris Life Sciences's consensus rating is Buy.
13 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $34.23.
Forecast evidence checked November 14, 2026.
Get free Caris Life Sciences email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $23.04
- Average price target
- $34.23
- High price target
- $38.00
- Low price target
- $25.00
- Low target gap
- +8.5%
- Target upside
- +48.6%
- High target gap
- +64.9%
- Target range width
- 56.4%
- Consensus rating
- Buy
- Analysts
- 13
- Evidence date
- November 14, 2026
- Valid through
- November 21, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Caris Life Sciences?
Caris Life Sciences has a verified Buy consensus. The same dataset has an average price target of $34.23.
How far are Caris Life Sciences's low and high targets from the recorded price?
The low target implies +8.5%, while the high target implies +64.9%.
How many analysts are included in Caris Life Sciences's consensus?
The verified consensus includes 13 analysts.
How is Caris Life Sciences's target upside or downside calculated?
The average target of $34.23 is divided by the recorded price of $23.04, then one is subtracted to produce +48.6%. This does not guarantee a future return.
When was Caris Life Sciences's analyst forecast verified?
The data was verified on 2026-11-14. The dataset is valid through 2026-11-21.